水腫臨床試驗市場－全球產業規模、佔有率、趨勢、機會和預測，按階段、參與者、申辦者、類型、地區和競爭格局分類，2020-2030年預測

2024年全球水腫臨床試驗市場規模為11.9億美元，預計2030年將以4.00%的複合年成長率成長至15.1億美元。全球水腫臨床試驗市場專注於研究評估用於治療水腫（即體內組織中液體異常積聚）的新型藥物、療法和醫療器材的安全性和有效性。

主要市場促進因素

全球範圍內與水腫相關的慢性疾病負擔日益加重，是推動臨床試驗市場發展的主要動力。隨著心臟衰竭、腎臟病和肝硬化等疾病盛行率的上升，水腫的併發率也顯著增加。

主要市場挑戰

進行全面的臨床試驗需要大量的資金投入，加上法規核准流程耗時較長，嚴重阻礙了全球水腫臨床試驗市場的成長。藥物研發所需的巨額資金投入，涵蓋從臨床前研究到所有階段人體試驗的各個環節，也成為製藥公司面臨的一大障礙。

主要市場趨勢

在水腫臨床試驗中，生物標記在個人化治療的應用日益廣泛，這是一個顯著的趨勢。這種方法透過識別可能對某種療法產生反應的特定患者亞群，促進藥物研發，從而提高試驗效率和治療效果。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球水腫臨床試驗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依階段（第一階段、第二階段、第三階段、第四階段）
  • 依參與者（兒科、成人科、老年科）分類
  • 贊助商（製藥公司、學術機構、政府機構）
  • 依類型（全身性水腫、局部性水腫）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美水腫臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲水腫臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區水腫臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲水腫臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲水腫臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球水腫臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Otsuka Holdings Co. Ltd.
• Novartis AG
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Sanofi SA
• AstraZeneca plc
• Bristol Myers Squibb India Pvt. Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Edema Clinical Trials Market, valued at USD 1.19 Billion in 2024, is projected to experience a CAGR of 4.00% to reach USD 1.51 Billion by 2030. The Global Edema Clinical Trials Market focuses on research studies evaluating the safety and efficacy of novel drugs, therapies, and medical devices developed to manage edema, which involves the abnormal accumulation of fluid in body tissues.

Key Market Drivers

The rising global burden of edema-associated chronic diseases is a primary impetus for the clinical trials market. As the prevalence of conditions like heart failure, kidney disease, and liver cirrhosis escalates, the concurrent incidence of edema increases significantly. This expanding patient demographic urgently requires advanced therapeutic interventions. According to the World Health Organization (WHO), in a fact sheet updated May 2023, noncommunicable diseases (NCDs) accounted for 41 million deaths annually in 2021, representing 74% of all global deaths, with many NCDs directly contributing to edema.

Key Market Challenges

The considerable financial investment required for conducting comprehensive clinical trials, coupled with extended timelines for regulatory approvals, presents a substantial impediment to the growth of the Global Edema Clinical Trials Market. The extensive capital outlay necessary for drug development, encompassing preclinical research through all phases of human trials, acts as a significant barrier for pharmaceutical companies.

Key Market Trends

The increased use of biomarkers for personalized treatment is a significant trend in edema clinical trials. This approach enhances drug development by identifying specific patient subpopulations likely to respond to a therapy, thereby improving trial efficiency and therapeutic outcomes. For example, in April 2025, research identified choroidal thickness (CCT) as a crucial biomarker for diabetic macular edema, where normal CCTs correlated with better treatment responses to aflibercept.

Key Market Players

• Otsuka Holdings Co. Ltd.
• Novartis AG
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Sanofi S.A.
• AstraZeneca plc
• Bristol Myers Squibb India Pvt. Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.

Report Scope:

In this report, the Global Edema Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Edema Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Edema Clinical Trials Market, By Participants:

• Pediatrics
• Adults
• Geriatrics

Edema Clinical Trials Market, By Sponsor:

• Pharmaceutical Companies
• Academic Institutions
• Government Bodies

Edema Clinical Trials Market, By Type:

• Systemic Edema
• Localized Edema

Edema Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Edema Clinical Trials Market.

Available Customizations:

Global Edema Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Edema Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Participants (Pediatrics, Adults, Geriatrics)
  • 5.2.3. By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies)
  • 5.2.4. By Type (Systemic Edema, Localized Edema)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Edema Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Participants
  • 6.2.3. By Sponsor
  • 6.2.4. By Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Edema Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Participants
      • 6.3.1.2.3. By Sponsor
      • 6.3.1.2.4. By Type
  • 6.3.2. Canada Edema Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Participants
      • 6.3.2.2.3. By Sponsor
      • 6.3.2.2.4. By Type
  • 6.3.3. Mexico Edema Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Participants
      • 6.3.3.2.3. By Sponsor
      • 6.3.3.2.4. By Type

7. Europe Edema Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Participants
  • 7.2.3. By Sponsor
  • 7.2.4. By Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Edema Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Participants
      • 7.3.1.2.3. By Sponsor
      • 7.3.1.2.4. By Type
  • 7.3.2. France Edema Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Participants
      • 7.3.2.2.3. By Sponsor
      • 7.3.2.2.4. By Type
  • 7.3.3. United Kingdom Edema Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Participants
      • 7.3.3.2.3. By Sponsor
      • 7.3.3.2.4. By Type
  • 7.3.4. Italy Edema Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Participants
      • 7.3.4.2.3. By Sponsor
      • 7.3.4.2.4. By Type
  • 7.3.5. Spain Edema Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Participants
      • 7.3.5.2.3. By Sponsor
      • 7.3.5.2.4. By Type

8. Asia Pacific Edema Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Participants
  • 8.2.3. By Sponsor
  • 8.2.4. By Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Edema Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Participants
      • 8.3.1.2.3. By Sponsor
      • 8.3.1.2.4. By Type
  • 8.3.2. India Edema Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Participants
      • 8.3.2.2.3. By Sponsor
      • 8.3.2.2.4. By Type
  • 8.3.3. Japan Edema Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Participants
      • 8.3.3.2.3. By Sponsor
      • 8.3.3.2.4. By Type
  • 8.3.4. South Korea Edema Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Participants
      • 8.3.4.2.3. By Sponsor
      • 8.3.4.2.4. By Type
  • 8.3.5. Australia Edema Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Participants
      • 8.3.5.2.3. By Sponsor
      • 8.3.5.2.4. By Type

9. Middle East & Africa Edema Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Participants
  • 9.2.3. By Sponsor
  • 9.2.4. By Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Edema Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Participants
      • 9.3.1.2.3. By Sponsor
      • 9.3.1.2.4. By Type
  • 9.3.2. UAE Edema Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Participants
      • 9.3.2.2.3. By Sponsor
      • 9.3.2.2.4. By Type
  • 9.3.3. South Africa Edema Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Participants
      • 9.3.3.2.3. By Sponsor
      • 9.3.3.2.4. By Type

10. South America Edema Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Participants
  • 10.2.3. By Sponsor
  • 10.2.4. By Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Edema Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Participants
      • 10.3.1.2.3. By Sponsor
      • 10.3.1.2.4. By Type
  • 10.3.2. Colombia Edema Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Participants
      • 10.3.2.2.3. By Sponsor
      • 10.3.2.2.4. By Type
  • 10.3.3. Argentina Edema Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Participants
      • 10.3.3.2.3. By Sponsor
      • 10.3.3.2.4. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Edema Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Holdings Co. Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Genentech, Inc.
• 15.4. Johnson & Johnson Services, Inc.
• 15.5. Merck & Co., Inc.
• 15.6. Sanofi S.A.
• 15.7. AstraZeneca plc
• 15.8. Bristol Myers Squibb India Pvt. Ltd.
• 15.9. GlaxoSmithKline plc
• 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer